Latest Insider Transactions at Vigil Neuroscience, Inc. (VIGL)
This section provides a real-time view of insider transactions for Vigil Neuroscience, Inc. (VIGL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Vigil Neuroscience, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Vigil Neuroscience, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 19
2024
|
Ivana Magovcevic Liebisch President and CEO |
BUY
Open market or private purchase
|
Direct |
5,000
+2.2%
|
$5,000
$1.68 P/Share
|
|
Dec 19
2024
|
Haeberlein Samantha L. Budd |
BUY
Open market or private purchase
|
Direct |
12,000
+50.0%
|
$12,000
$1.71 P/Share
|
|
Dec 18
2024
|
Ivana Magovcevic Liebisch President and CEO |
BUY
Open market or private purchase
|
Direct |
5,000
+2.25%
|
$5,000
$1.67 P/Share
|
|
Dec 05
2024
|
Ivana Magovcevic Liebisch President and CEO |
BUY
Open market or private purchase
|
Direct |
5,000
+2.3%
|
$10,000
$2.34 P/Share
|
|
Nov 20
2023
|
Ivana Magovcevic Liebisch President and CEO |
BUY
Open market or private purchase
|
Direct |
4,000
+1.89%
|
$12,000
$3.75 P/Share
|
|
Nov 18
2022
|
Spyridon Papapetropoulos Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
300
-6.98%
|
$4,200
$14.0 P/Share
|
|
Nov 18
2022
|
Spyridon Papapetropoulos Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
300
+6.52%
|
$300
$1.89 P/Share
|
|
May 17
2022
|
Clay Thorp Director |
BUY
Open market or private purchase
|
Indirect |
14,893
+0.95%
|
$29,786
$2.97 P/Share
|
|
May 16
2022
|
Clay Thorp Director |
BUY
Open market or private purchase
|
Indirect |
21,802
+1.39%
|
$43,604
$2.76 P/Share
|
|
May 05
2022
|
Evan Thackaberry SVP, Head of Early Development |
BUY
Open market or private purchase
|
Direct |
1,500
+50.0%
|
$6,000
$4.0 P/Share
|
|
May 03
2022
|
Spyridon Papapetropoulos Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
4,000
+50.0%
|
$12,000
$3.4 P/Share
|
|
May 03
2022
|
Jennifer Lynn Ziolkowski Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
4,000
+50.0%
|
$12,000
$3.77 P/Share
|
|
May 03
2022
|
Christopher Verni General Counsel |
BUY
Open market or private purchase
|
Direct |
4,000
+50.0%
|
$12,000
$3.77 P/Share
|
|
May 03
2022
|
Ivana Magovcevic Liebisch President and CEO |
BUY
Open market or private purchase
|
Direct |
1,000
+0.49%
|
$3,000
$3.94 P/Share
|
|
May 02
2022
|
Ivana Magovcevic Liebisch President and CEO |
BUY
Open market or private purchase
|
Direct |
4,000
+1.94%
|
$12,000
$3.61 P/Share
|
|
Mar 28
2022
|
Clay Thorp Director |
BUY
Open market or private purchase
|
Direct |
3,000
+50.0%
|
$21,000
$7.2 P/Share
|
|
Jan 11
2022
|
Cormorant Asset Management, LP |
BUY
Conversion of derivative security
|
Indirect |
616,786
+50.0%
|
-
|
|
Jan 11
2022
|
Alexandria Venture Investments, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
192,973
+50.0%
|
-
|
|
Jan 11
2022
|
Northpond Ventures Gp, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
355,000
+20.43%
|
$4,970,000
$14.0 P/Share
|
|
Jan 11
2022
|
Northpond Ventures Gp, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,859,498
+50.0%
|
-
|
|
Jan 11
2022
|
Stefan Vitorovic |
BUY
Open market or private purchase
|
Indirect |
1,675,000
+25.03%
|
$23,450,000
$14.0 P/Share
|
|
Jan 11
2022
|
Stefan Vitorovic |
BUY
Conversion of derivative security
|
Indirect |
3,340,929
+50.0%
|
-
|
|
Jan 11
2022
|
Bruce Booth |
BUY
Open market or private purchase
|
Indirect |
535,000
+10.01%
|
$7,490,000
$14.0 P/Share
|
|
Jan 11
2022
|
Bruce Booth |
BUY
Conversion of derivative security
|
Indirect |
3,859,498
+44.93%
|
-
|
|
Jan 11
2022
|
Atlas Venture Fund Xii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
535,000
+10.01%
|
$7,490,000
$14.0 P/Share
|
|
Jan 11
2022
|
Atlas Venture Fund Xii, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,859,498
+44.93%
|
-
|
|
Jan 11
2022
|
Vida Ventures Gp Iii, L.L.C. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,675,000
+25.03%
|
$23,450,000
$14.0 P/Share
|
|
Jan 11
2022
|
Vida Ventures Gp Iii, L.L.C. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,340,929
+50.0%
|
-
|
|
Jan 11
2022
|
Clay Thorp Director |
BUY
Open market or private purchase
|
Indirect |
265,000
+14.85%
|
$3,710,000
$14.0 P/Share
|
|
Jan 11
2022
|
Clay Thorp Director |
BUY
Conversion of derivative security
|
Indirect |
1,254,335
+50.0%
|
-
|
|
Jan 11
2022
|
Amgen Inc > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
3,206,281
+50.0%
|
-
|